Clinical Skincare Contract Manufacturer. Where the Chemistry Has to Hold Up.
Clinical-grade treatments, performance actives, and hybrid formulations — developed and produced in Chicago by a degreed cosmetic chemist with 10+ years across retail and indie beauty.
The category where credentials matter most.
Clinical and performance skincare is the segment where a degreed cosmetic chemist is not a nice-to-have — it is a prerequisite. The formulations are active-forward, the concentration ranges are tighter, the stability behavior is less forgiving, and the claims framework has to survive scrutiny from retailers, dermatologists, and informed consumers.
Formula 117 is a clinical skincare contract manufacturer built for exactly that tier of work. A degreed cosmetic chemist with 10+ years across major retail and indie beauty brands designs the formulations — multi-active serums, clinical-grade retinoid systems, high-concentration vitamin C, peptide stacks, and hybrid treatment formats that blur the line between cosmetic and functional.
This is not the vertical for brands looking for the fastest or cheapest path to market — for that, see private label or general skincare manufacturing. It is the vertical for brands whose formulation has to hold up under technical scrutiny — and where the chemist behind the product is the actual competitive advantage. Most clinical work routes through custom formula development.
Three specialty tracks, one chemist.
High-concentration active formulations — retinoid systems, multi-acid peels, peptide stacks, clinical-grade vitamin C. Tight concentration ranges, validated stability, claims-ready documentation. For brands selling into dermatology channels or clinical-adjacent retail.
Active-forward products that push beyond standard cosmetic concentrations — niacinamide at efficacious doses, bakuchiol alternatives, encapsulated delivery systems, multi-pathway treatment serums. Formulated to outperform the commodity tier.
Products that cross traditional category lines — serum-moisturizer hybrids, treatment oils with water-phase actives, overnight mask-treatments, tinted serums with active payloads. Novel formats that require emulsion architecture and active compatibility engineering.
What we can build.
Common questions.
What makes clinical skincare contract manufacturing different from standard cosmetic manufacturing?+
Active concentrations, stability complexity, and claims burden. Clinical-grade formulations push higher concentrations of actives like retinoids, vitamin C, and peptides — which creates tighter stability windows, more demanding preservation requirements, and formulation challenges that standard cosmetic manufacturing does not encounter. The chemist has to design around those constraints, not around a template.
Can Formula 117 formulate retinoid and vitamin C systems?+
Yes. Retinoid systems (retinol, retinal, hydroxypinacolone retinoate, encapsulated formats) and vitamin C systems (L-ascorbic acid, ethylated ascorbic acid, SAP) are core clinical formulation work. Each system has specific pH, stability, and packaging requirements that the chemist addresses during formulation. Stability protocols are especially critical for these actives.
What is the MOQ for clinical skincare manufacturing?+
500 units per SKU, same as all Formula 117 verticals. Per-unit manufacturing settles at $2–$3+ at 2,500–5,000 unit volumes. Clinical formulation is project-quoted based on active complexity, not a flat per-unit number. Expect the formulation phase to run longer than standard skincare due to stability and compatibility demands.
Do you handle hybrid or cross-category product formats?+
Yes. Hybrid treatments — serum-moisturizer crossovers, treatment oils with water-phase actives, tinted serums with active payloads, overnight mask-treatments — are formulated as novel emulsion systems. The chemist designs the architecture to deliver both the active payload and the sensorial expectation of the format. These typically require custom stability protocols.
How long does clinical skincare formulation take compared to standard skincare?+
Longer. Custom clinical formulations typically run toward the upper end of the 19–30 week range — sometimes beyond — because active stability is less forgiving, concentration validation takes more bench iterations, and preservation systems need to account for pH-sensitive actives. The 12-week stability protocol is fixed; the formulation phase is where timelines stretch.
Ready to start production?
Send your project details. You'll hear back within 48–72 hours with next steps.
Start a Project